RaQualia Pharma Inc.
4579.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.38 | -0.00 | 3.99 | -0.02 |
| FCF Yield | 0.40% | 0.16% | -3.90% | -0.58% |
| EV / EBITDA | 15,823.37 | -66.67 | 53.17 | 1,777.02 |
| Quality | ||||
| ROIC | -2.69% | -3.22% | -0.19% | -2.43% |
| Gross Margin | 70.77% | 58.76% | 69.67% | 68.99% |
| Cash Conversion Ratio | -0.33 | -0.16 | 57.83 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.71% | 9.16% | 5.11% | 2.12% |
| Free Cash Flow Growth | 184.22% | 106.24% | -550.16% | -116.33% |
| Safety | ||||
| Net Debt / EBITDA | -576.86 | 1.22 | 3.58 | 77.63 |
| Interest Coverage | -10.14 | -17.48 | 6.22 | -13.29 |
| Efficiency | ||||
| Inventory Turnover | 1.23 | 1.37 | 1.71 | 1.36 |
| Cash Conversion Cycle | 114.06 | 157.59 | 141.75 | 126.65 |